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Abstract 
The synthetic cannabinoid WIN 55,212-2 is a potent cannabinoid receptor agonist with anticancer 
potential. Experiments were performed to determine the effects of WIN on proliferation, cell 
cycle distribution, and programmed cell death in human osteosarcoma MG63 and Saos-2 cells. 
Results show that WIN induced G2/M cell cycle arrest, which was associated with the induction of 
the main markers of ER stress (GRP78, CHOP and TRB3). In treated cells we also observed the 
conversion of the cytosolic form of the autophagosome marker LC3-I into LC3-II (the lipidated 
form located on the autophagosome membrane) and the enhanced incorporation of mono-
dansylcadaverine and acridine orange, two markers of the autophagic compartments such as 
autolysosomes. WIN also induced morphological effects in MG63 cells consisting in an increase in 
cell size and a marked cytoplasmic vacuolization. However, WIN effects were not associated with 
a canonical apoptotic pathway, as demonstrated by the absence of specific features, and only the 
addition of TRAIL to WIN-treated cells led to apoptotic death probably mediated by up-regulation 
of the tumor suppressor factor PAR-4, whose levels increased after WIN treatment, and by the 
translocation of GRP78 on cell surface. 
Key words: Cannabinoids, ER stress, autophagy, TRAIL, osteosarcoma cells, GRP78/PAR-4 com-
plex. 
Introduction 
Osteosarcoma is the most common malignant 
bone tumor in childhood and adolescence. Although 
the tumor can initially respond to chemotherapy, in 
patients with metastatic disease the prognosis re-
mains adverse [1]. Therefore, a better understanding 
of osteosarcoma biology should be helpful to optimize 
treatment strategies, or develop new chemotherapeu-
tic agents.  
Cannabinoids (CBs), the active constituents of 
Cannabis sativa, are known to exert a wide range of 
central and peripheral effects. Recently, numerous 
studies evidenced the role of cannabinoids in the reg-
ulation of cell death and survival, focusing the an-
ti-proliferative effects of these compounds in various 
tumours [2-5]. Cannabinoids can trigger several dif-
ferent signalling pathways. Following the interaction 
with the specific CB1 and CB2 receptors, cannabinoids 
have been shown to induce accumulation of ceramide 
[6-7] or activation of c-Jun N-terminal kinase (JNK) 
and p38 MAPK [8], as well as, increase in calcium 
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concentration, ROS production, inhibition of PKA or 
NF-kB and modulation of pro- and anti-apoptotic 
members of the Bcl-2 family [9-10].  
Recently, it has been demonstrated that canna-
binoids can also activate autophagic process, an evo-
lutionarily conserved mechanism that occurs in all 
eukaryotic cells [11]. In the first phase of autophagy a 
portion of the cytoplasm and other intracellular or-
ganelles are sequestered in double-membrane struc-
tures called autophagosomes. This process requires 
the formation of a multiprotein complex associated 
with the conjugation of phosphatidylethanolamine to 
microtubule-associated protein light chain 3 (LC3) 
and the conversion of soluble form LC3-I to au-
tophagic vesicle-associated LC3-II form. Then, the 
autophagosomes fuse with lysosomes to form au-
tolysosomes where the sequestered contents are de-
graded by lysosomal hydrolases and recycled in the 
cytosol. However, the effects of these events on cancer 
cells are not well known. A large body of evidence 
indicates a role for autophagy in sustaining cell sur-
vival [12]. In contrast, cell death resulting from pro-
gressive cellular consumption has been attributed to 
unrestrained autophagy, which can replace the clas-
sical apoptotic pathway, or cooperate with it [13]. 
In a recent study, it has been demonstrated that 
in human glioma cells, the main experimental model 
for the studies on cannabinoid action, the natural 
cannabinoid delta(9)-tetrahydrocannabinol induces 
autophagy-mediated cell death through stimulation 
of ER stress [14]. However the exact role exerted by 
autophagy in cannabinoid action remains unclear. 
The aim of the present study was to investigate 
the effects induced by cannabinoids in osteosarcoma 
cells and the molecular pathway by them activated. 
Results indicated that in this experimental model the 
synthetic cannabinoid WIN 55,212-2 (WIN) induces 
morphological changes which are not associated with 
the induction of cell death but with the triggering of 
ER stress and autophagic process. These events make 
WIN able to sensitizing TRAIL-resistant MG63 and 
Saos-2 cells to TRAIL-induced apoptosis. Moreover, 
we indicate that a key role in WIN action is played by 
the tumor suppressor protein PAR-4. 
Materials and Methods  
Reagents 
R-[2,3-Dihydro-5-methyl-3[(4-morpholinyl)meth
yl] pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthal
enyl methanone mesylate (WIN55,212-2), anan-
damide (ANA), meth-anandamide (MethANA), 
3-methyl-adenine (3-MA) and BAPTA-AM were 
purchased from Sigma, soluble human recombinant 
TRAIL/APO2L was obtained from PeproTech (EC 
Ltd., London, UK), benzyloxy-carbonyl-Val-Ala- 
Asp-fluoromethylketone (z-VAD-fmk) from Promega 
(Madison, WI). Stock solutions were prepared in 
DMSO and opportunely diluted in culture medium 
except for 3-MA which was prepared in ethanol. The 
final concentration of DMSO or ethanol never ex-
ceeded 0.04%, which is a concentration that was ex-
perimentally determined to have no discernible effect. 
All antibodies used were purchased from Santa Cruz 
Bio (Santa Cruz, CA, USA), except for an-
ti-procaspase-3, procaspase-8, Beclin-1 and PARP 
(Cell Signalling, Beverly, MA, USA), anti-LC3 (Novus 
Biologicals, Cambridge, UK), p62 and Actin (Sigma, 
MI, Italy).  
Cell cultures 
Human osteosarcoma MG63 and Saos-2 cells 
were acquired from Interlab Cell Line Collection 
(ICLC, Genova, Italy). Cells were cultured at 37° C in 
Dulbecco’s modified Eagle medium (DMEM), sup-
plemented with 10% (v/v) heat-inactivated foetal 
bovine serum (FBS), 2.0 mM L-glutamine, and antibi-
otic, anti-mycotic solution (100 U/ml penicillin, 100 
µg/ml streptomycin and 250 ng/ml amphotericin B, 
Sigma) in a humidified atmosphere containing 5% 
CO2. For the experiments, cells were seeded at 60-70% 
confluence. After overnight incubation, culture me-
dium was replaced with fresh DMEM containing low 
percentage of FBS (2%) and cells were treated with the 
compounds. Control cells were cultured in the pres-
ence of vehicle alone.  
Cell viability assay 
Cell viability was determined by 
3-[4,5-dimethylthiazolyl- 2] 2,5-diphenyl-tetrazolium 
bromide (MTT) (Sigma Aldrich, Milan, Italy) assay as 
previously reported [15]. Briefly, after treatment in 
96-well plates (triplicate wells for each sample), MTT 
stock solution was added to each well (final concen-
tration 1 mg/ml) for 2 h. The medium was then re-
moved and lysis buffer (0.1 ml) was added to dissolve 
the formazan product. Finally, the absorbance at 570 
nm (test wavelength) and at 630 nm (reference wave-
length) was measured using an ELISA microplate 
reader (Dynex Technologies). Data reported in the 
figures are the means ± S.E. of at least four inde-
pendent experiments involving triplicate assays. 
For acridine orange/ethidium bromide staining 
(AO/EB), cells were incubated on 96-well plates, 
treated with the compounds and stained with a solu-
tion composed of 100 µg/ml acridine orange plus 100 
µg/ml ethidium bromide. Cells were examined under 
a Leica DM IRB inverted microscope (Leica Mi-
crosystems Srl, Milano, Italy) equipped with epifluo-
rescence optics and suitable filters for FITC and rho-
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damine detection. Viable cells appear with green nu-
clei and dead cells have bright orange chromatin. 
Images were photographed and captured by a com-
puter-imaging system (Leica DC300F camera and 
Adobe Photoshop for image analysis).  
Cell cycle analysis 
To analyse cell cycle distribution, after treatment 
with the compounds, cells were harvested by tryp-
sinization (0.025% trypsin-EDTA; Life Technologies 
Ltd, Monza, Italy) and resuspended in a hypotonic 
solution containing 25 µg/ml propidium iodide, 0.1% 
sodium citrate, 0.01% Nonidet P-40 and 10 µg/ml 
RNase A. The cell cycle phase distribution was eval-
uated by Coulter Epics XL flow cytometer (Beckman 
Coulter) using Expo32 software. Cell debris and ag-
gregates were excluded by opportune gating. The 
percentage of cells in subG0/G1 phase was consid-
ered as an index of DNA fragmentation. The red flu-
orescence was measured in the FL3 channel using a 
620 nm BP filter. At least 1 x 104 cells per sample were 
analyzed and data were stored in list mode files. 
The results showed in the figures are repre-
sentative of four independent experiments. 
Autophagy analysis 
Autophagy was examined by staining cells with 
acridine orange (AO) (2 µg/ml in PBS) at 37°C for 15 
min in the dark. Images of AO staining were imme-
diately visualized by fluorescence microscopy. To 
quantify the number of acidic vesicles, after staining 
with AO the cells were washed with PBS and ana-
lyzed by flow cytometric assay. 
The formation of acidic vesicular organelles was 
also detected by monodansylcadaverine (MDC) 
staining. Cells were stained with 0.05 mM MDC in 
PBS at 37°C for 15 min. Following the incubation, cells 
were washed three times with PBS and immediately 
analyzed under fluorescence microscope by using 
DAPI filter. 
Western blotting analysis 
Protein extracts were prepared by washing the 
cells in PBS and incubating for 20 min in ice-cold lysis 
buffer supplemented with protease inhibitor cocktail, 
as previously reported [16]. After sonication for three 
times for 10 s, proteins were quantified by Bradford 
method and equal amount of proteins (40 µg) was 
separated by SDS-PAGE and then electrotransferred 
to a nitrocellulose membrane for the detection with 
specific antibodies. The blots were developed using 
the alkaline phosphatase colorimetric or ECL chemi-
luminescent labeling systems. Optical densities of the 
bands were analyzed with Quantity One Imaging 
Software from Bio-Rad Laboratories. The correct pro-
tein loading was verified by means of both Ponceau 
red staining and immunoblotting for actin. The results 
showed in the figures are representative of almost 
four independent experiments with similar results. 
Gene silencing using siRNA 
Small interfering RNAs (siRNAs) against CHOP 
(siCHOP) (D-004819-01-0005 and D-004819-02-0005) 
and scrambled siRNA (siScr), as a negative non-
silencing control, were purchased from Dharmacon 
RNA Technologies (Chicago, IL USA).  
Cells (105) were seeded in six well plates and 
cultured in antibiotic-free DMEM medium supple-
mented with 2.0 mM L-glutamine, to reach about 50% 
confluence. Then, cells were transfected with 100 nM 
siCHOP in the presence of 6.2 µl Metafectene Pro 
(Biontex Laboratories GmbH, Martinsried/Planegg, 
Germany) in a final volume of 1 ml serum-free me-
dium. The reaction was stopped after 6 h replacing the 
culture medium with DMEM +10% FBS and then si-
lenced cells were treated with the compounds after 24 
h. In CHOP silencing experiments, data reported were 
obtained by using siRNA duplex D-004819-02-0005 
which resulted more efficacious than 
D-004819-01-0005. 
Detection of surface GRP78 in 
non-permeabilized cells 
To analyse cell surface GRP78, after treatment 
with the compounds, cells were washed, fixed, and 
incubated overnight with GRP78 primary antibody 
(H-129, Santa Cruz) in PBS containing 0.1% BSA at 
4°C. Subsequently, cells were washed with PBS, in-
cubated with FITC-conjugated secondary antibody for 
1 h at 4°C. As controls, cells were incubated with the 
secondary IgG alone. Cell nuclei were counterstained 
with cell-permeant dye Hoechst 33342. Cells were 
examined under a Leica DM IRB inverted microscope 
(Leica Microsystems Srl, Milano, Italy) equipped with 
epifluorescence optics and suitable filters for FITC. 
Images were photographed and captured by a com-
puter-imaging system (Leica DC300F camera and 
Adobe Photoshop for image analysis).  
To quantify the level of cell surface GRP78, cells 
were harvested by trypsinization and resuspended in 
PBS containing 0.1% BSA, adjusting cell concentration 
to 1x106 cells/ml. Then, the cells, without fixing to 
allow detection of GRP78 at the cells surface, were 
incubated with GRP78 antibody (H-129, Santa Cruz) 
or isotype control for 30 min at 4°C. Then, cells were 
washed twice in 1 ml PBS to remove excess antibody. 
Appropriate volume of FITC-conjugated secondary 
antibody was added and cell suspension was incu-
bated for 30 min at 4°C in the dark. Cells were washed 
twice in 1ml PBS, resuspended in 0.5 ml PBS and ac-
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quired by using Coulter Epics XL flow cytometry 
(Beckman-Coulter) and Expo 32 software.  
Statistical analysis 
Cell viability data were expressed as the mean ± 
S.E. and evaluated by Student’s t-test. Differences 
were considered significant when the p value was less 
than 0.05. 
Results  
Cytotoxic and morphological effects induced 
by cannabinoids in MG63 osteosarcoma cells 
To examine whether cannabinoids can influence 
osteosarcoma cell proliferation, MG63 cells were 
treated for different times with various doses of the 
endogenous cannabinoid anandamide (ANA), its sta-
ble analogue meth-anandamide (MethANA), or syn-
thetic cannabinoid WIN55,212-2 (WIN). Fig. 1A shows 
the results obtained after 48 h of treatment on cell 
viability measured by means of MTT assay. At the 
highest dose employed (20 µM), only WIN induced a 
significant reduction of cell number (about 50%), 
while the other cannabinoids induced modest effects. 
Time course analysis of WIN effect showed that the 
reduction of cell number was already evident after 8 h 
of treatment, as reported in Fig. 1B. 
 
 
Figure 1. Cytotoxic and morphological effects induced by cannabinoids in human osteosarcoma MG63 cells. (A) Effects of anandamide (ANA), meth-anandamide 
(MethANA) and WIN on MG63 cell viability. Cells were incubated for 48 h with different doses (5, 10 and 20 µM) of cannabinoids. (B) Time and dose-dependent effects of WIN 
on MG63 cell viability and effect of 100 µM z-VAD in cells treated with 5 µM WIN for 36 h. In A and B, cell survival was estimated by MTT assay, as reported in Materials and 
Methods, and expressed as the percentage of control cells. Data are the means ± S.E. of four independent experiments involving triplicate assays. **p<0.01 versus untreated cells. 
(C) Fluorescent microscopic evaluation of MG63 cells after acridine orange/ethidium bromide staining (AO/EB). Cells were treated with 5 µM ANA, MethANA and WIN for 36 
h. Then, after AO/EB staining, viable cells appear with green nuclei, while dead cells show red nuclei. (Original magnification 200X). (D) Morphological effects induced by 
cannabinoids after 36 h of treatment evaluated by phase contrast microscopy. (Original magnification 200X). The inset shows a magnification of the cell indicated by the arrow. 
In C and D, the images are representative of three independent experiments. 
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Table 1. Effects of cannabinoids on MG63 cell cycle distribution. 
Cells were treated with cannabinoids for 36 h. Both floating and 
attached cells were collected and processed for analysis of cell 
cycle distribution by flow cytometry following staining with pro-
pidium iodide. The percentage of cells in each phase of the cell 
cycle was calculated using Expo32 software. Data are means ± S.E. 
of three independent experiments. 
 
 
 
Next, we aimed to address whether the cell 
number reduction was a consequence of apoptotic cell 
death. For this purpose, cells were visualized under 
fluorescent microscopy after acridine or-
ange/ethidium bromide staining. WIN treatment in-
duced a non-significant induction of apoptosis; cells 
appeared with a diffuse green staining and only few 
red fluorescent nuclei, indicative of cell death, were 
observed (Fig. 1C). Also Hoechst 33258 staining 
seemed to indicate the absence of nuclear fragmenta-
tion (not shown). Moreover, the lack of canna-
binoid-dependent MG63 cell death was confirmed by 
the analysis of cell distribution in the different phases 
of cell cycle which did not show relevant differences 
in the percentage of cells in sub G0/G1 phase of cell 
cycle indicative of DNA fragmentation. In the pres-
ence of WIN, we only observed an increase in the 
percentage of cells in G2/M phase which reached 
about 27% after 36 h of 5 µM WIN treatment (Table 1). 
Similar effects were obtained also after long periods of 
treatment (48 h) in the presence of WIN at the highest 
dose (20 µM) (Supplementary Fig.1). Moreover, the 
addition of 100 µΜ z-VAD to WIN-treated cells did 
not induce any variation in cell viability with respect 
to cells treated with WIN alone, thus confirming the 
failure of WIN to induce apoptosis (Fig. 1B and sup-
plementary Fig. 1). 
Light microscopy analysis showed morphologi-
cal aberrations in MG63 cells treated with canna-
binoids. 5 µM ANA or MethANA induced the ap-
pearance of elongated, translucent and isolated cells. 
Differently, 5 µM WIN induced an increase in cell 
size, cytoplasmic contraction and the appearance of 
many vacuolar structures (Fig.1D).  
WIN triggers endoplasmic reticulum stress in 
MG63 osteosarcoma cells and induces the 
appearance of autophagic hallmarks 
It is known that in many different experimental 
models cannabinoids act through a molecular mech-
anism that involves the induction of endoplasmic 
reticulum (ER) stress [14]. Thus, we were interested to 
study this relationship in our experimental model. 
Initially, in WIN-treated cells, we analysed the level of 
proteins which are considered ER stress markers such 
as CHOP, TRB3 and GRP78/Bip (GRP78). As shown 
in Fig. 2A, the level of CHOP, a transcription factor 
induced by cellular stresses such as protein misfold-
ing in ER, time-dependently increased after treatment 
with 5 µM WIN. The effect was evident at 8 h of 
treatment reaching the maximum at 36 h. In the same 
time, also the level of TRB3, a target of CHOP, and 
GRP78, the main reticular HSP70, increased after WIN 
treatment in time-dependent manner.  
Then, since it has been largely demonstrated the 
relationship between ER stress and cytoplasmic vac-
uolization [17], we investigated the effects of silencing 
the expression of the ER stress marker CHOP. After 
confirming the efficiency of CHOP silencing (not 
shown), we evaluated cell morphology in 
WIN-treated CHOP-silenced cells. As shown in Fig. 
2B, CHOP silencing completely counteracted intra-
cellular vacuolar formation induced by WIN, being 
cell morphology very similar to that observed in con-
trol cells. To further demonstrate the dependence of 
WIN-induced vacuolization by ER stress, we em-
ployed BAPTA-AM, a chelator of intracellular calci-
um. The addition of BAPTA-AM to WIN-treated cells 
counteracted cytoplasmic vacuolization both in 
non-silenced and CHOP-silenced MG63 cells (Fig. 2B). 
In the same way, BAPTA-AM also counteracted 
WIN-dependent increase in expression level of ER 
stress markers CHOP and GRP78 (Fig. 2C), confirm-
ing the dependence of WIN-induced morphological 
effect on ER stress.  
Then, we analysed whether the induction of ER 
stress was correlated with the activation of autophagic 
pathway. The microtubule-associated protein 1 light 
chain 3 (LC3), a marker of the presence of autopha-
gosomes [18], is activated by a cleavage of the cyto-
solic form LC3-I to LC3-II, and recruited to double 
layered membrane of autophagosomes [19]. Im-
munoblotting analysis showed that the band corre-
sponding to LC3-II increased in cells exposed to WIN 
in time-dependent manner reaching the maximum 
after 16 h of treatment (Fig. 3A). Differently, no varia-
tion was found in the level of Beclin1, a marker for 
autophagosome formation. The analysis of p62, a 
multifunctional protein involved in selective au-
tophagy and considered as a marker to study au-
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tophagic flux [20], showed a progressive reduction of 
protein level, indicative of protein degradation.  
The autophagic response to WIN was also stud-
ied by using monodansylcadaverine (MDC), a marker 
for the acidic compartment of autolysosomes [21]. As 
shown in Fig. 3B, treatment of MG63 cells with 5 µM 
WIN for 16 h caused the accumulation of punctate 
fluorescent structures, distributed within the cyto-
plasm or localized in the perinuclear regions. Acidic 
organelles (AVOs) were also detected after staining 
the cells with acridine orange (AO), a weak base that 
moves freely across biological membranes when un-
charged. In AO-stained cells, the cytoplasm and nu-
cleolus fluoresce bright green and dim red, whereas 
acidic compartments fluoresce bright red [22]. Fluo-
rescent microscopic analysis showed that the number 
of acidic vesicles in WIN-treated MG63 cells increased 
compared to untreated cells (Fig. 3C). Data were con-
firmed by flow cytometric examination which evi-
denced the increase in the intensity of red fluores-
cence in WIN-treated cells (Fig. 3D).  
In order to confirm the involvement of the au-
tophagic pathway, 5 mM 3-methyladenine (3-MA), an 
inhibitor of the early stages of autophagy [23] was 
added to WIN-treated cells. In these conditions, a 
marked reduction of the number of fluorescent spots 
was already observed after 16 h of treatment (Fig. 3B, 
C and D).  
 
Figure 2. WIN induces endoplasmic reticulum stress in osteosarcoma MG63 cells. (A) Time-dependent effect of 5 µM WIN and 5 ng/ml TRAIL on the level of CHOP, 
TRB3 and GRP78. The results were obtained by immunoblotting employing specific antibodies as reported in Materials and Methods. (B) Morphological effects exerted by the 
addition of BAPTA-AM to non-silenced or CHOP-silenced MG63 cells. Silencing of CHOP expression was carried out as reported in Materials and Methods. Cytoplasmic 
vacuolization was analysed by phase contrast microscopy after treatment for 24 h with 5 µM WIN and/or 5 µM BAPTA-AM. (Original magnification 200X). The images are 
representative of three independent experiments. (C) Effects of BAPTA-AM on the levels of CHOP and GRP78 proteins. Western blotting analysis was performed after 
treatment for 36 h with the compounds. In A and C, actin blots were included as a loading control. 
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Figure 3. WIN causes the appearance of autophagic hallmarks in MG63 cells. (A) Time-dependent effect of 5 µM WIN employed alone or in combination with 5ng/ml 
TRAIL on the level of non-lipidated (LC3-I) and lipidated (LC3-II) forms of LC3, Beclin1 and p62. The levels of autophagic specific markers were analysed after 8, 16, 36 h of 
treatment. Cell lysates were analysed by immunoblotting employing specific antibodies as reported in Materials and Methods. Actin blots were included as a loading control. 
(B-C) Evaluation of autophagic vacuoles induced by WIN treatment, and effect of the autophagic inhibitor, 3-methyladenine (3-MA). MG63 cells were treated for 16 h with 5 µM 
WIN in the presence or absence of 5 mM 3-MA. After treatment, cells were incubated with MDC (0.05 mM) (B) or AO (2 µg/ml) (C) for 15 min at 37 °C and analyzed using a 
fluorescent microscope as described in Materials and Methods. (Original magnification 400X). The images are representative of three independent experiments. (D) Flow 
cytometric examination of red fluorescence emission (FL3) in WIN (red line) and WIN/3MA (green line) -treated cells with respect to control untreated cells (blue line). After 
incubation with the compounds, cells were treated with 2µg/ml AO for 15 min at 37 °C. The plot is representative of three independent experiments. 
 
WIN/TRAIL combined treatments induce 
apoptotic cell death mediated by PAR-4 
protein. 
In a previous study, we demonstrated the ability 
of WIN to sensitize hepatocellular carcinoma cells to 
TRAIL-induced apoptosis [24]. Thus, we were inter-
ested to investigate the effects of the addition of dif-
ferent doses of TRAIL to cannabinoids in MG63 cells. 
MTT assay confirmed that MG63 cells are resistant to 
TRAIL (10 ng/ml), while the addition of TRAIL to 
WIN-treated cells resulted in a marked 
time-dependent reduction of cell viability which 
reached about 80% of the control value after 36 h (Fig. 
4A). Differently, ANA/TRAIL or MethANA/TRAIL 
combinations (also at high doses) were almost inef-
fective in increasing the effects induced by canna-
binoids alone (Fig. 4A).  
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Figure 4. WIN/TRAIL combined treatments induce apoptotic cell death. (A) Effects of cannabinoids and TRAIL on MG63 cell viability. Cells were treated with ANA, 
MethANA, WIN employed alone or in combination with TRAIL for 36 h at the indicated concentrations. (B) Morphological changes induced by WIN/TRAIL combined treatment 
in MG63 cells. Cells were treated for 36 h with 5 µM WIN and/or 5 ng/ml TRAIL and analysed by phase contrast microscopy. (Original magnification 200X). The images are 
representative of three independent experiments. (C) Effects of WIN/TRAIL combined treatment on MG63 cell cycle distribution. Flow cytometric analysis was carried out on 
propidium iodide stained cells treated for 36 h with WIN and/or TRAIL. The percentage of cells in each phase of the cell cycle was calculated using Expo32 software. (D) Effects 
of the addition of 5 mM 3-MA or 100 µM z-VAD to WIN or WIN/TRAIL treated cells for 36 h. In A and D, MG63 cell viability was estimated by MTT assay as reported under 
Materials and Methods and expressed as the percentage of control value. Data are the means ± S.E. of four independent experiments involving triplicate assays. **, p<0.01 versus 
untreated cells. (E) Western blotting analysis of caspase-8, pro-caspase-3 and PARP levels in MG63 cells. After treatment for 36 h with 5 µM WIN and/or TRAIL, cell lysates were 
analysed via immunoblotting using specific antibodies as reported in Materials and Methods. Actin blots were included as a loading control.  
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The reduction of viability induced by 
WIN/TRAIL combined treatment was accompanied 
by induction of cell death as demonstrated by light 
microscopic analysis which evidenced the appearance 
of the typical features of apoptosis consisting in 
rounded, detached cells floated in the medium (Fig. 
4B). Apoptotic pathway was also confirmed by the 
analysis of cell cycle distribution. As shown in Fig. 4C 
in WIN/TRAIL treated cells the percentage of cells 
confined in sub G0/G1 phase of cell cycle increased, 
reaching a percentage of about 34% at 36 h of treat-
ment. 
The addition of 100 µM z-VAD to WIN/TRAIL 
treated cells counteracted cytotoxicity; in fact, after 36 
h of treatment, the percentage of residual viability 
was comparable to that observed in cells treated with 
WIN alone (Fig. 4D). Western blotting analysis of the 
level of caspase proteases evidenced that WIN in-
duced only a modest activation of caspase-8 while 
after WIN/TRAIL combined treatment we observed a 
marked reduction in the inactive, pro-enzymatic 
forms of caspase-8 and -3 and the concomitant ap-
pearance of the lower molecular weight, active frag-
ments of caspase-8, indicative of activation of the ex-
trinsic apoptotic pathway (Fig. 4E). The activation of 
executioner caspase-3 was also confirmed by the 
concomitant caspase-dependent cleavage of 
Poly-(ADP-ribose) polymerase (PARP), a target of 
caspase-3, which was evident in WIN/TRAIL treated 
cells (Fig. 4E). Taken together, data indicated that 
WIN was able to sensitize MG63 cells to TRAIL, in-
ducing a canonical caspase-dependent apoptotic 
pathway. 
Western blotting analysis showed that in 
WIN/TRAIL treated cells ER stress and autophagic 
protein markers remained at high levels (similar to 
those observed in the presence of WIN alone) after 
short incubation time points while after prolonged 
treatment we observed a modest decrease in the levels 
of proteins which can probably be dependent on the 
high percentage of dead cells (Fig. 2A and 3A). 
To better investigate the contribution of au-
tophagic process in cell death induced by 
WIN/TRAIL combined treatment we analyzed the 
effect of the addition of the autophagic inhibitor 3-MA 
on viability of WIN/TRAIL-treated cells. As shown in 
Fig. 4D, after 36 h of treatment with 5 mM 3-MA, the 
cytotoxic effects induced by WIN/TRAIL combined 
treatment were reduced.  
Finally, we wondered what was the link between 
the ability of WIN to induce ER stress and the sensi-
tization of MG63 cells to TRAIL action. Some evidence 
indicates that the tumor suppressor protein PAR-4 
(Prostate Apoptosis Response-4, also known as 
PAWR) is able to activate apoptotic pathway by in-
teracting with GRP78 and inducing its translocation 
on cell surface [25] where GRP78 behaves as a recep-
tor for soluble ligands to induce apoptosis [26]. To 
explore the possible involvement of this pathway, we 
firstly analyzed the expression level of PAR-4 in 
WIN-treated cells. As shown in Fig. 5A, the level of 
PAR-4 increased after 8 and 16 h of treatment with 
WIN and further in WIN/TRAIL treated cells, indi-
cating an actual involvement of this factor in the early 
phases of apoptotic process. In the presence of TRAIL 
alone, no variation in the level of PAR-4 was observed 
(not shown). Then, we detected the presence of GRP78 
on cell membrane of non-permeabilized WIN-treated 
MG63 cells by immunofluorescence microscopy. As 
shown in Fig. 5B (upper panel), a marked increase in 
green fluorescence, indicative of an enhanced GRP78 
expression on cell surface, was observed after WIN 
treatment for 24 h. The results were quantified by 
cytofluorimetric analysis that indicated an increase of 
about 2.5-fold in green fluorescence (lower panel). 
To analyze the relationship between ER stress, 
PAR-4 expression and cytotoxicity induced by 
WIN/TRAIL combined treatment, we analyzed the 
level of PAR-4 in CHOP silenced cells. As shown in 
Fig. 5C, in siCHOP WIN-treated cells the level of 
PAR-4 markedly lowered, indicating a plausible de-
pendence of PAR-4 level on CHOP activity. Lastly, in 
CHOP silenced cells we also observed a significant 
recovery of cell viability (Fig. 5D).  
Effects of WIN or WIN/TRAIL combined 
treatment in human osteosarcoma Saos-2 
cells. 
Then, to evaluate whether the effects induced by 
WIN in MG63 cells could be reproduced in other os-
teosarcoma cell lines we performed some experiments 
in Saos-2 cells. 
Fig. 6A shows the effects on cell viability in-
duced in Saos-2 cells by anandamide (ANA), 
meth-anandamide (MethANA), or WIN55,212-2 
(WIN) after 48 h of treatment. It is possible to observe 
that also in this cell line WIN was the most efficacious 
drug among the employed cannabinoids although 
overall its effects were slightly less evident than in 
MG63 cells. Moreover, time course analysis confirmed 
the results obtained in MG63 cells (Fig. 6B).  
Similarly to MG63 cells, in Saos-2 cells WIN and 
WIN/TRAIL combined treatment induced ER stress 
and autophagy as demonstrated by the increase in the 
levels of CHOP and GRP78 (Fig. 6C) and in those of 
LC3 (Fig. 6D) while, also in these cells, it was not ob-
served any variation in the level of Beclin-1 (Fig. 6D). 
WIN/TRAIL combined treatment resulted in a 
marked reduction of Saos-2 cell viability which was 
almost entirely counteracted by the addition of 100 
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µM z-VAD indicating an involvement of caspase ac-
tivities in this event (Fig. 6E). Finally, in WIN or 
WIN/TRAIL treated cells we demonstrated a clear 
increase in the level of the tumor suppressor protein 
PAR-4 (Fig. 6F) thus suggesting a common mecha-
nism that accounts for the effects of the drug in oste-
osarcoma cells. 
Discussion 
In this study we explored the effects induced by 
cannabinoids in osteosarcoma MG63 and Saos-2 cells. 
We found that among the three cannabinoids tested 
(the endogenous cannabinoid anandamide, its stable 
analogue meth-anandamide, and the synthetic can-
nabinoid WIN), only WIN caused a clear reduction in 
cell number and morphological alterations that, 
however, were not accompanied by induction of cell 
death. In particular, very interesting was the observa-
tion that WIN treatment induced cytoplasmic vacu-
olization in MG63 cells clearly visible under light mi-
croscopy. This event, which is normally calci-
um-dependent, may originate from multiple intra-
cellular organelles such as endoplasmic reticulum, 
endosomes and lysosomes and can be interpreted as a 
specific phase of autophagic process [27]. Moreover, it 
is well known the relationship between cell vacuoli-
zation and ER stress and between cannabinoids and 
ER stress induction. Wasik et al. reported that in 
mantle cell lymphoma (MCL) cells WIN induces cy-
toplasmic vacuolization which originates from ER and 
is associated to programmed cell death of type III [28]. 
The observed up-regulation of CHOP, TRB3 and 
GRP78, the main ER stress markers, in MG63 cells 
supported the involvement of ER stress in 
WIN-induced vacuolization which was also con-
firmed by the loss of vacuolar structures observed 
both in CHOP-silenced WIN treated cells and in cells 
co-treated with WIN and BAPTA-AM, a chelator of 
intracellular calcium. Interestingly, the addition of 
BAPTA-AM also counteracted WIN-induced 
up-regulation of ER-stress markers, strongly sustain-
ing the hypothesis that the increase in intracellular 
calcium level can be an early event in WIN pathway. 
 
Figure 5. WIN treatment induces PAR-4 upregulation and cell surface GRP78 translocation. (A) Time dependent effect of WIN or WIN/TRAIL combined 
treatment on the level of PAR-4 protein. After treatment with 5 µM WIN employed alone or in combination with 5 ng/ml TRAIL, cell lysates were analysed by immunoblotting 
using a specific antibody as reported in Materials and Methods. (B) Effects of WIN treatment on surface GRP78 levels. Upper panel: Determination of surface GRP78 by 
immunofluorescence. Cells were treated for 24 h with 5 µM WIN, incubated with anti-GRP78 antibody followed by FITC-conjugated secondary antibody and analyzed using an 
inverted fluorescent microscope as described in Materials and Methods. Nuclei were counterstained with Hoechst 33342 (blue). Lower panel: Cytometric analyses showing cell 
surface expression of GRP78 in MG63 cells. The open histograms indicate isotype control, filled histograms indicate the expression of GRP78 in untreated and WIN-treated cells. 
(C) PAR-4 level in CHOP-silenced cells. Silencing of CHOP expression was carried out as reported in Materials and Methods. After WIN treatment cell lysates were analysed 
by immunoblotting using specific antibody as reported in Materials and Methods. In A and C, actin blots were included as a loading control. (D) Effects of WIN/TRAIL combined 
treatment in CHOP silenced cells. Silencing of CHOP expression was carried out as reported in Materials and Methods. Cells were treated with 5 µM WIN and/or 5 ng/ml TRAIL 
for 24 h. MG63 cell viability was estimated by MTT assay as reported under Materials and Methods and expressed as the percentage of control value. Data are the means ± S.E. 
of four independent experiments involving triplicate assays. **, p<0.01 versus control untreated cells. 
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Figure 6. Effects of WIN and WIN/TRAIL treatment on Saos-2 cells. (A) Effects of anandamide (ANA), Meth-anandamide (MethANA) and WIN on Saos-2 cell viability. 
Cells were incubated for 48 h with different doses (5, 10 and 20 µM) of cannabinoids. (B) Time and dose-dependent effects of WIN on Saos-2 cell viability. In A and B, cell survival 
was estimated by MTT assay, as reported in Materials and Methods, and expressed as the percentage of control cells. Data are the means ± S.E. of three independent experiments 
involving triplicate assays. *, p<0.01 versus untreated cells. (C) Effect of WIN and/or WIN/TRAIL combined treatment on the level of CHOP and GRP78 proteins. (D) 
Time-dependent effect of WIN on the level of Beclin-1 and LC3 protein. (E) Effects of WIN or WIN/TRAIL combined treatment on Saos-2 cell viability. Cells were treated with 
WIN (5 µM) employed alone or in combination with TRAIL at the indicated concentrations. The effect of caspase inhibitor z-VAD (100 µM) at 36 h of treatment is also shown. 
Cell viability was estimated by MTT assay as reported in Materials and Methods and expressed as the percentage of control value. Data are the means ± S.E. of three independent 
experiments involving triplicate assays. *, p<0.01 versus control untreated cells. (F) Effect of WIN and/or WIN/TRAIL combined treatment on the level of PAR-4 protein. For 
western blotting analysis, after treatment with the compounds, cell lysates were analysed using specific antibodies as reported in Materials and Methods. Actin blots were included 
as a loading control. 
 
Frequently, ER stress is related to autophagic 
process [14]. Depending on the cell context, autoph-
agy can counterbalance ER stress induction for cell 
survival or switch the cytoprotective function into cell 
death promoting pathway. The results obtained in 
osteosarcoma cells showed that WIN treatment in-
duced the activation of LC3, an autophagosome 
marker, by promoting the cleavage of its cytosolic 
form LC3-I to LC3-II. The involvement of autophagy 
was also confirmed by the augmented accumulation 
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of acidic intracellular compartments. Moreover, the 
observation that the level of p62 protein, a marker of 
autophagic degradation, decreased after long periods 
of WIN treatment, together with the appearance of 
acidic vacuoles suggested that WIN triggered a com-
plete autophagic response, differently from that ob-
served in MCL cells [28]. 
In spite of the induction of ER stress and au-
tophagy, low doses of WIN were not capable to trig-
ger significant cell death in osteosarcoma cell lines. 
However, such as previously demonstrated in hepa-
tocellular carcinoma cells [24], WIN sensitized MG63 
and Saos-2 cells to apoptosis induced by TRAIL, a 
promising anticancer agent [29-30]. Data reported in 
this paper indicate that the addition of low doses of 
TRAIL to WIN-treated cells was able to inhibit osteo-
sarcoma cell growth (about 80% of cell viability re-
duction after 36 h of treatment) which was accompa-
nied by the typical morphological and biochemical 
features of apoptotic cell death, as confirmed by the 
employment of the caspase inhibitor z-VAD. Also in 
this case, the endogenous cannabinoids showed a 
different behaviour than WIN; the addition of TRAIL 
to anandamide or meth-anandamide, in fact, did not 
modify the effects induced by the cannabinoids em-
ployed alone. Presently, we cannot explain the dif-
ferent response of MG63 cells to these combined 
treatments and new experiments are in progress to 
verify a potential connection between the induction of 
cytosolic vacuolization and the sensitization to 
TRAIL. 
The observation that the addition of autophagy 
inhibitor 3-MA counteracted the cytotoxicity induced 
by WIN/TRAIL combined treatment suggested an 
involvement of autophagic process in WIN/TRAIL 
induced cell death. It has been reported that following 
TRAIL exposure cancer cells can induce a cytoprotec-
tive autophagy that blunts apoptosis and TRAIL an-
titumoral effect can be enhanced in the presence of 
autophagy inhibitors [31]. However, mounting evi-
dence has suggested that autophagy can also be con-
sidered a caspase-dependent or -independent death 
pathway. In a recent paper Jin et al [32] observed that 
in papillary thyroid cancer cells autophagy inhibition 
desensitized cells to TRAIL-induced apoptosis even if 
the authors did not propose any hypothesis to explain 
the mechanism.  
The crosstalk between apoptosis and autophagy 
in inducing cell death is strongly sustained by the 
observations that several molecules required for au-
tophagy also play a key role in the regulation of 
apoptosis and viceversa [33-34]. In this connection, it 
has been demonstrated that the autophagosomal 
membrane can serve as a platform for the intracellular 
activation of caspase-8 thus permitting to initiate 
caspase cascade and apoptotic cell death [35]. In ac-
cordance to this evidence, our preliminary observa-
tions (data not shown) seem to indicate that in 
WIN/TRAIL treated cells the addition of autophagy 
inhibitor 3-MA counteracted the activation of caspa-
se-8. This evidence could explain the role of autoph-
agy in WIN-induced sensitization to TRAIL. Howev-
er, further investigations are necessary to confirm this 
relationship. 
After establishing the sensitization to TRAIL ac-
tion induced by WIN, we further identified PAR-4 as 
a probable downstream factor. PAR-4, a tumor sup-
pressor protein initially identified in prostate cancer 
cells, is characterized by the ability to selectively in-
duce apoptosis in cancer cells through both an intra-
cellular and an extrinsic pathway [36]. Although 
PAR-4 is often down-regulated in cancer, its 
re-expression sensitizes cancer cells, but not normal 
cells, to death following to oncogene inhibition or 
chemotherapy. It has been demonstrated that PAR-4 
activates the translocation of Fas and FasL to the cell 
membrane and, at the same time, it inhibits the 
pro-survival transcriptional factor NF-κB [37-38]. Re-
cently, it has been reported a relationship between 
PAR-4 and GRP78. In an elegant paper, Burikhanov et 
al [25] proposed a novel regulatory loop that involves 
the translocation of GRP78 to cell surface mediated by 
intracellular PAR-4 and its successive interaction with 
extracellular PAR-4. This mechanism can correlate ER 
stress with the activation of extrinsic apoptotic path-
way. In osteosarcoma cells we observed a marked 
increase in PAR-4 level after WIN or WIN/TRAIL 
combined treatment and a concomitant translocation 
of GRP78 to cell surface. Differently from the Authors, 
we did not observe any increase in PAR-4 level in the 
presence of TRAIL alone, suggesting that the en-
hancement of PAR-4 level is related to ER stress in-
duced by WIN. This hypothesis was confirmed by the 
reduction in PAR-4 level observed following to the 
silencing of ER stress marker CHOP which is accom-
panied by the recovery of cytotoxicity induced by 
WIN/TRAIL combined treatment.  
Taken together, although some important ques-
tions remain to be further clarify, here we hypothesize 
a novel mechanism, described in Fig. 7, through 
which WIN induces ER stress-dependent activation of 
autophagy and, in the same time, increases PAR-4 
level and GRP78 translocation on cell surface. These 
events, together with autophagy-mediated activation 
of caspase-8, could contribute to the formation of a 
membrane microdomain and be responsible, directly 
or indirectly, for the sensitization to TRAIL action.  
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Figure 7. Suggested model of the mechanism of WIN/TRAIL-induced apoptosis on osteosarcoma MG63 cells. 
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